clinical trial · NCT06830850
A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
Atridia Pty Ltd.·phase1·recruiting·n = 25
Metastatic Castration Resistant Prostate CancerHRS-5041 Single dose of HRS-5041 orally administered
brief summary
To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.
started
Jun 15, 2025
primary completion
Dec 30, 2026
completion
Mar 15, 2027
last updated
Jan 15, 2026
official title
A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol